Skip to main content

As demand for Covid vaccines falls, AstraZeneca lines up 'blockbuster' products for 2023

Demand for Covid-19 vaccines has dropped, but AstraZeneca has "blockbuster" projects in development that are set to make billions of dollars, according to its CFO.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.